Clinical Trials
12 trialsNCT02362997 2026-05-18
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03927105 2026-05-07
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT05255601 2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
NCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02264613 2026-01-13
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
Phase 1/2 Completed
NCT06511895 2025-12-24
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Dizal Pharmaceuticals
Phase 2 Completed
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04018248 2025-09-10
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
Phase 1 Completed
NCT03496779 2025-07-30
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT06511869 2025-07-04
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Dizal Pharmaceuticals
Phase 2 Completed